Our Investigators
PCCTC investigators are internationally recognized leaders from over 300 of the world's top academic medical centers, and sponsors work with them directly. Drawing on their insight into the underlying biology of the disease, they developed the universally adopted clinical states model of prostate cancer and initiated one of the first efforts in oncology to prospectively validate endpoints for definitive phase 3 studies (PCWG2, followed by PCWG3), criteria now embedded in trial protocols across the field and updated in 2026 with the publication of PCWG4. For a sponsor, this means trial designs shaped by the people who wrote the standards: advisory input, endpoint strategy, and site-level engagement come from the same investigators whose research objectives run through our study portfolio.
Our Consortium
Since its inception in 2005, the PCCTC has grown from a network of eight preeminent academic institutions to a multinational consortium of more than 200 participating academic and community-based clinical research sites. For sponsors, the consortium is operating infrastructure, not an affiliation: standing site relationships, streamlined contracting, and shared processes that shorten start-up and sustain accrual. That infrastructure also powers consortium-led programs in imaging, blood-based biomarkers, clinical study design, germline genetics, and targeted therapy development, so industry studies inherit the same platforms academic investigators use to advance the field. It now supports a portfolio reaching beyond prostate cancer into a diverse array of oncology indications.
Therapy Development
The PCCTC selects and prioritizes development opportunities on three tests: our knowledge of the global drug development landscape, the strength of the underlying science, and the potential to address critical unmet needs across the cancers we study. Close interaction between basic scientists and clinical investigators moves promising therapies into early-phase studies quickly, while novel study designs, endpoints, and predictive biomarkers facilitate efficient, objective decisions around advancing or discontinuing a program.
Biomarker Development
The PCCTC develops therapies and biomarkers together. Drugs advance faster in precisely defined, biologically relevant patient groups: screening for likely responders shortens development timelines and spares patients unnecessary toxicity from ineffective treatment. PCCTC investigators have shaped how the field measures prostate cancer for more than two decades, from the original PSA Working Group eligibility and response guidelines through the PCWG2, PCWG3, and PCWG4 criteria that now define PSA-, imaging-, and biomarker-based endpoints in trial protocols worldwide, including PCWG4's criteria for PSMA-PET. For sponsors, the objective is direct: analytically valid assays and clinically validated intermediate endpoints that can predict clinical benefit and support accelerated approval.
